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http://www.biomedcentral.com/1472-6823/13/37RESEARCH ARTICLE Open AccessEffects of physical activity on the development
and progression of microvascular complications
in type 1 diabetes: retrospective analysis of the
DCCT study
Caroline BT Makura1, Krishnarajah Nirantharakumar2, Alan J Girling2, Ponnusamy Saravanan3
and Parth Narendran1,4,5*Abstract
Background: To examine the effects of physical activity on the development and progression of microvascular
complications in patients with type 1 diabetes.
Methods: A retrospective analysis of data from the Diabetes Control and Complications trial was undertaken.
Physical activity data was collected at baseline for each of 1441 recruits, converted to metabolic equivalent of task
values, and categorised according to the American College of Sports Medicine recommendations. The rates of
development/progression of diabetic retinopathy, nephropathy and neuropathy were compared in those who
achieved over twice recommended, up to twice recommended, and less than recommended metabolic equivalent
of task levels of activity. The DCCT study had a mean duration of follow up of 6.5 years ending in 1993.
Results: A total of 271 subjects had a sustained three-step progression in diabetic retinopathy. The rates of
development or progression of retinopathy showed no significant association with physical activity level. The
number of outcomes for nephropathy and neuropathy were small and there was no significant association with
physical activity level.
Conclusions: We found no evidence that physical activity improves microvascular outcomes in type 1 diabetes.
However we demonstrate no evidence of harm. We suggest that physical activity continues to play an important
role in the management of type 1 diabetes.
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The evidence for benefit of physical activity in type 1 dia-
betes is poorly delineated. Whilst it improves wellbeing,
lipid profile and macrovascular disease in type 1 diabetes
[1,2], there is limited evidence for benefit to blood pres-
sure, glucose control or microvascular diseases such as
retinopathy, nephropathy and neuropathy [3]. We set out
to determine whether physical activity protects against* Correspondence: p.narendran@bham.ac.uk
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reproduction in any medium, provided the ormicrovascular complications, the consequences of dia-
betes that are often patients’ biggest fear [4,5].
To date, cross-sectional studies have demonstrated
that microvascular complications are associated with de-
creased physical activity in patients with type 1 diabetes
[6]. Causality however has not been demonstrated, and
this association could be explained by the presence of
complications impairing the ability to undertake physical
activity, rather than physical activity decreasing the com-
plications of diabetes. In one study where adult patients
with type 1 diabetes were asked to estimate their phys-
ical activity during teenage years have reported anLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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development of nephropathy and neuropathy [7]. How-
ever this inverse association was seen only in males, and
was not seen for retinopathy. Although this study con-
trolled for a number of important factors such as dur-
ation of diabetes, and baseline HbA1c, the subjective
and retrospective estimation of physical activity weakens
these findings.
To examine whether physical activity protects against
microvascular complications in a more accurate and lon-
gitudinal fashion, we chose to examine publicly available
high quality data from the Diabetes and Complications
Trial (DCCT) [8]. This is a large randomised controlled
trial originally designed to examine whether good glu-
cose control prevents microvascular complications. The
study also provides detailed physical activity levels as
well as accurate data on all the other predictors of
microvascular diseases in Type 1 diabetes. No other pro-
spective dataset exists, and it is therefore a powerful tool
with which to examine the area of interest.
Methods
Ethics statement
Ethical approval was obtained for each of the 29 study
centres across USA and Canada for the DCCT study
from the Hospital for Sick Children Research Ethics
Board. All study participants provided written informed
consent.
Study design, participants and intervention
Anonymised data from the Diabetes Control and Com-
plication Trial (DCCT) [8] was obtained with ethical ap-
proval. Here, patients with type 1 diabetes aged between
13 to 39 years were divided into either the primary
(726pts) or secondary (715pts) prevention cohort. The
primary prevention cohort had no evidence of micro-
vascular complications, and diabetes for less than 5 years.
Those in the secondary prevention cohort had diabetes
less than 15 years, minimal-moderate retinopathy and
urinary albumin excretion rate of less than 200 mg per
24 hours. Each cohort was randomised to receive either
intensive or standard glucose lowering therapy.
Exposure of interest (Leisure time physical activity)
At entry into the study, each patient was asked to specify
the amount of time spent in leisure time physical activity
(LTPA) of different intensities for the previous seven
days. These activities were converted to Metabolic
Equivalent of Task (MET) values - the median MET
value for each level of activity described in the question-
naire was calculated using previously defined criteria [9]
and used for data analysis. According to the inter-
national classification by Ainsworth used by American
College of Sports Medicine (ACSM), ‘light’ activity wasallocated 3 METs, ‘moderate’ activity (defined as 3–6
METs) was allocated of 4 METs, ‘hard activity’ 6 METs
and ‘very hard activity’ 9 METs. For each participant, we
multiplied this allocated median MET value by the time
(minutes) spent in that activity to obtain the MET for
that level of activity. The sum of METs from all activities
was recorded as the total leisure time activity for each
participant at entry into the DCCT. All participants were
categorised into three groups based on the ACSM rec-
ommendation for METs.min/week (450-750METs) [10]:
those who did not achieve the recommended level of
METs for a given week (<450METs), those achieving
recommended to twice the recommended level (450-
1500METs), and those achieving more than twice the
recommended METS (>1500METs).Outcome measure
Progression of retinopathy was defined to have occurred
if there was a sustained (6 months) change of three steps
or more from baseline on the Early Treatment Diabetic
Retinopathy Study (ETDRS) scale [11]. Nephropathy was
defined as albumin excretion rate (AER) of >40 mg/
24 hour [12,13]. Each participant was examined quar-
terly every year and the time to progression of retinop-
athy and occurrence of nephropathy was recorded.
Neuropathy was assessed by clinical examination and
confirmed by either abnormal nerve conduction or auto-
nomic nervous system testing or both at a fixed time
point of 5 years follow up [14]. Patients with nephropa-
thy and neuropathy at baseline were excluded from the
analysis in order to study onset of complications [13,14].
Covariates included duration of diabetes, baseline
HbA1c, triglycerides, cholesterol, diastolic and systolic
blood pressure, BMI and smoking status. Occupational
activity representing physical activity at work, school or
home was also recorded by DCCT specific questionnaire
as three categories namely sedentary (such as office
work with occasional inter-office walking), moderate
(work requiring considerable but not constant, lifting,
walking, bending and pulling) and strenuous activity (re-
quires almost constant lifting, bending, pulling, scrub-
bing etc.).
The DCCT study was followed by a subsequent study
called Epidemiology of Diabetes Interventions and Com-
plications (EDIC). Here the patients who had partici-
pated in the DCCT study were unblinded and asked to
remain in follow-up to determine the effect of the
DCCT intervention on complications in the longer term.
We did not consider using the EDIC dataset because the
exposure of interest was at DCCT baseline and therefore
the time interval between exposure and outcome was
too long to make a meaningful interpretation. Further-
more the EDIC data only recorded presence of outcome
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or nephropathy.
Statistical analysis
Analysis was carried out separately for each of the inten-
sive and standard glucose lowering therapy arms of the
DCCT trial. We chose to analyse the data in this way be-
cause glucose lowering is now established to protect
from microvascular complications and would have been
an important confounder. One-way analysis of variance
test was used to compare continuous variables and the
chi-square test was used to compare the categorical vari-
ables in the three LTPA groups.
Kaplan Meier survival curves (with the retinopathy
and nephropathy as endpoint) were generated for the
three LTPA groups stratified according to the primary
and secondary prevention cohort. Initially we used log-
rank test in each arm stratified according to the preven-
tion cohort to compare LTPA groups. This was
supplemented by a multivariate Cox regression analysis
with stratification by primary and secondary prevention
cohort. In this regression model we controlled for age,
gender, duration of diabetes, baseline HbA1c value and
occupational activity.
Given the smaller number of outcomes and fixed time
point for neuropathy, only a univariate analysis (Chi-
square test) was performed. Analysis was conducted in
the SPSS 18 statistical package.Table 1 Baseline characteristics of the leisure time physical ac
study
Standard treatment
Category1
(N=130)
Category 2
(N=194)
Categor
(N=387
#Age (Years) 28.7(5.9) 27.8(6.8) 25.0(7
#Duration of diabetes (Months) 62.8(50.0) 67.4(49.2) 65.7(48
#HbA1c 9.1(1.9) 9.0(1.6) 9.1(1
#Cholesterol(mg/dl) 179.6(36.1) 177.5(34.8) 173.3(31
#Triglycerides(mg/dl) 82.4(54.0) 81.0(42.3) 82.0(54
#BMI (Kg/m2) 23.5(2.9) 23.5(2.9) 23.4(2
#DBP (mmHg) 72.6(8.6) 72.6(8.7) 73.0(9
#SBP (mmHg) 113.0(11.5) 114.7(11.3) 115.4(12
*Primary prevention cohort % 57.4 46.9 5
*Male % 47.5 54.1 5
*Current smoker % 29.1 22.7 1
*Occupational activity
Sedentary % 37.6 33.3 2
Moderate % 53.9 59.9 6
Vigorous % 8.5 6.8
Category 1 = METS less than 450
Category 2 = METS 450-1500Category 3 = METS > 1500. # Mean (Standard De
* Percentage.Results and discussion
The baseline characteristics of the patients enrolled in
the study are shown in Table 1 stratified according to
trial arm. Mean age of all 1441 participants was
26.8 years with 52.8% being males. Interestingly, the
population appears to be very active with only 20% of
the patient group not meeting recommended levels of
activity. Follow-up was for a mean of 6.5 years (range 3
to 9). LTPA was positively associated with younger age
in both arms of the trial (P <0.01), and with male sex
and non-smoking status in the intensive arm of the trial.
There was no association between LTPA and HbA1c,
cholesterol, triglycerides, blood pressure or BMI at trial
entry (P>0.05). There was no difference in LTPA be-
tween the standard and intensive arms of the trial.
Kaplan-Meir survival analysis did not reveal any
difference in progression of retinopathy in the three in-
cremental physical activity categories either in the in-
tensive or standard treatment arm when stratified
according to cohort (Log-rank test Intensive Chi2 3.14;
P=0.21 and standard Chi2 0.93;P=0.63) (Figure 1). In
the multivariate analysis the hazard ratios (HR) were
not significant, either in the recommended to twice
recommended (adjusted HR, 95%CI:0.93 (0.41-2.09)) or
in the above twice recommended (adjusted HR, 95%
CI:1.13 (0.73-1.77)) categories in the intervention arm.
Similarly it was not significant in the standard treat-
ment arm (Figure 1).tivity groups in intensive and standard arms of DCCT
Intensive treatment
y 3
)
P value Category 1
(N=141)
Category 2
(N=207)
Category 3
(N=382)
P value
.4) <0.01 29.4(6.1) 28.2(6.5) 25.8(7.4) <0.01
.6) 0.70 74.7(51.3) 69.2(51.0) 68.2(50.4) 0.45
.5) 0.66 9.3(1.7) 8.9(1.5) 9.1(1.6) 0.18
.8) 0.11 176.3(30.3) 179.1(34.7) 176.4(32.7) 0.62
.8) 0.97 77.7(43.2) 78.5(38.1) 83.1(45.6) 0.32
.9) 0.88 23.3(2.8) 23.4(2.7) 23.3(2.7) 0.76
.0) 0.82 71.5(8.7) 72.5(8.9) 72.5(8.9) 0.51
.0) 0.12 113.1(11.3) 113.5(12.0) 113.4(11.4) 0.95
2.4 0.14 48.5 46.9 50.1 0.76
6.5 0.19 40.8 43.8 58.9 <0.001
8.3 0.11 26.9 20.6 18.3 0.03
6.4 0.06 29.2 35.6 26.7 0.09
6.8 64.6 58.8 64.8
6.8 6.2 5.7 8.5
viation).
Figure 1 (See legend on next page.)
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Figure 1 Kaplan-Meier survival curves and hazard ratios for retinopathy in the DCCT dataset according to LPA (data is categorised
according to Standard / Intensive treatment arm, and Primary / Secondary prevention cohort). Data is categorised according to Standard /
Intensive treatment arm, and Primary / Secondary prevention cohort and each curve is stratified according to the three categories of Metabolic
Equivalent of Tasks. Panel A shows the primary cohort in the Intensive arm, Panel B shows the primary cohort in the standard treatment arm,
Panel C shows the secondary cohort in the intensive treatment arm and Panel D shows the secondary cohort in the standard treatment arm.
Both the survival curves in panels A and C show a higher cumulative survival rate when compared to the survival graphs in Panel B and D.
However, Kaplan-Meier analysis of the survival graphs did not demonstrate any difference in progression of retinopathy in the three incremental
physical activity categories in either the intensive or standard treatment arm. Log-rank test for the intensive arm Chi2 is 3.14 (P=0.21) and Log-
rank test for the standard treatment arm Chi2 is 0.93 (P=0.63). Separation in the curves seen towards the end of the graphs is indicative of the
fewer numbers followed up for a longer period.
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neuropathy were small (97 for nephropathy and 28 for
neuropathy). We did however undertake an analysis of
the effect of LTPA on the progression of these complica-
tions, but were not able to detect any association (see
Additional files 1 and 2). Further analysis with all
patients (combined primary/secondary cohort, standard/
intensive treatments) provided similar results.
Conclusion
In this large prospective interventional study, we ob-
served the physical activity levels were higher than the
average population [15]. Only 20% of the patients did
not meet the recommended daily physical activity levels.
This may be due to positive selection bias (patients
volunteered are also motivated to do physical activity).
Current modifiable risk factors for microvascular com-
plications in type 1 diabetes are recognised to be gly-
caemic control, blood pressure, lipids, insulin resistance
and smoking [16-18]. Of these, glycaemic control is ar-
guably the most powerful predictor of retinopathy.
There is no conclusive evidence for the role of physical
activity on microvascular complications. In this detailed
analysis of the DCCT study, we also found no evidence
that leisure time physical activity protects against either
the development or progression of microvascular com-
plications in type 1 diabetes. This lack of benefit in our
analysis may be explained by the weak glycaemic benefit
of exercise in type 1 diabetes [19-21]. We also speculate
such lack of benefit may also be due to temporary de-
terioration in the glycaemic control due to reduction in
insulin doses to avoid hypoglycaemia, though no such
data is available in the study. However, we believe this
study is better suited to examining the effect of exercise
on the progression of microvascular complications, than
previous cross sectional [6] and retrospective studies [7],
whose results it contradicts.
The main limitation of our study is the fact that it is a
post hoc analysis. The DCCT study is neither designed
nor powered to test whether physical activity protects
from microvascular complications. Despite the lack of
validation of the physical activity types at data collection,
the study is unique as the leisure time and occupationalactivity data in the study are detailed. Another limitation
is that the levels of physical activity may have varied dur-
ing the course of the study, making a baseline assess-
ment unrepresentative. Whilst the DCCT is now a dated
study and diabetes practices will likely have changed in
the past 20 years, we do not believe this invalidates the
use of the dataset to examine our research question.
In summary, our study does not support a benefit of
physical activity on microvascular complications in pa-
tients with type 1 diabetes. However, a prospective
randomised controlled study will be required to address
this question adequately. In the mean time, it would be
advisable to continue to support a program of physical
activity in patients with type 1 diabetes for its benefits
on wellbeing, macrovascular disease and mortality.
Additional files
Additional file 1: Kaplan-Meier survival curves and hazard ratios for
nephropathy. N=1365, sustained albuminuria >=40mg /24 hrs and
excludes patients with albuminuria >=40mg/24 hrs at baseline in the
DCCT dataset. Data is categorised according to Standard / Intensive
treatment arm, and Primary / Secondary prevention cohort and each
curve is stratified according to the three categories of Metabolic
Equivalent of Tasks. Panel A shows the primary cohort in the Intensive
arm, Panel B shows the primary cohort in the standard treatment arm,
Panel C shows the secondary cohort in the intensive treatment arm and
Panel D shows the secondary cohort in the standard treatment arm. Both
the survival curves in panels A and C show a higher cumulative survival
rate when compared to the survival graphs in Panel B and D with those
in the primary cohort and Intensive arm demonstrating the highest
cumulative survival rate. A total of 97 subjects developed nephropathy.
Kaplan-Meier analysis of the survival graphs suggested a difference in
progression of nephropathy for the Standard arm stratified on primary
and secondary prevention cohort in the three incremental physical
activity categories (Log rank test: Chi2 6.61, P=0.04). However in the
adjusted multivariate cox regression analysis there was no demonstrable
significant associations (Hazard ratio 0.52 (0.22-1.21) for recommended
and up to twice recommended and 0.99 (0.49-1.98) for more than twice
recommended). There were no significant trend or associations noted in
the more relevant intensive treatment arm.
Additional file 2: Neuropathy analysis based on 5 year outcome of
neuropathy as defined by DCCT group. 1161 patients, who were free
of neuropathy at baseline were followed. A total of 108 patients
presented with neuropathy at 5 years of which 28 of were in the
Experimental treatment arm and 80 in the Standard treatment arm.
Analysis was carried out in the Control arm and Treatment arm tables
stratified on primary and secondary prevention cohort in the three
incremental physical activity categories. There were no demonstrable
association noted in either arm of the study (p>0.05).
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